title: Community-wide measures of wellness in a remote First Nations community experiencing opioid dependence: evaluating outpatient buprenorphine-naloxone substitution therapy in the context of a First Nations healing program.
abstract: OBJECTIVE
  To document the development of unique opioid-dependence treatment in remote communities that combines First Nations healing strategies and substitution therapy with buprenorphine-naloxone.
  
  
  METHODS
  Quantitative measurements of community wellness and response to community-based opioid-dependence treatment.
  
  
  METHODS
  Remote First Nations community in northwestern Ontario.
  
  
  METHODS
  A total of 140 self-referred opioid-dependent community members.
  
  
  METHODS
  Community-developed program of First Nations healing, addiction treatment, and substitution therapy.
  
  
  METHODS
  Community-wide measures of wellness: number of criminal charges, addiction-related medical evacuations, child protection agency cases, school attendance, and attendance at community events.
  
  
  RESULTS
  The age-adjusted adult rate of opioid-dependence treatment was 41%. One year after the development of the in-community healing and substitution therapy program for opioid dependence, police criminal charges had fallen by 61.1%, child protection cases had fallen by 58.3%, school attendance had increased by 33.3%, and seasonal influenza immunizations had dramatically gone up by 350.0%. Attendance at community events is now robust, and sales at the local general store have gone up almost 20%.
  
  
  CONCLUSIONS
  Community-wide wellness measures have undergone dramatic public health changes since the development of a First Nations healing program involving opioid substitution therapy with buprenorphine-naloxone. Funding for such programs is ad hoc and temporary, and this threatens the survival of the described program and other such programs developing in this region, which has been strongly affected by an opioid-dependence epidemic.
authors.forename: Dinah
authors.initials: D
authors.lastname: Kanate
authors.forename: David
authors.initials: D
authors.lastname: Folk
authors.forename: Sharon
authors.initials: S
authors.lastname: Cirone
authors.forename: Janet
authors.initials: J
authors.lastname: Gordon
authors.forename: Mike
authors.initials: M
authors.lastname: Kirlew
authors.forename: Terri
authors.initials: T
authors.lastname: Veale
authors.forename: Natalie
authors.initials: N
authors.lastname: Bocking
authors.forename: Sara
authors.initials: S
authors.lastname: Rea
authors.forename: Len
authors.initials: L
authors.lastname: Kelly
mesh_terms: D000328:Adult; D002047:Buprenorphine / Q000008:administration & dosage / Q000627:therapeutic use*; D003153:Community Health Services / Q000379:methods; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009270:Naloxone / Q000008:administration & dosage / Q000627:therapeutic use*; D009864:Ontario; D058850:Opiate Substitution Treatment / Q000379:methods*; D009293:Opioid-Related Disorders / Q000188:drug therapy / Q000523:psychology / Q000534:rehabilitation*; D010045:Outpatients / Q000523:psychology*; D055815:Young Adult
chemical_list: D009270:Naloxone; D002047:Buprenorphine
references.citation: J Subst Abuse Treat. 2010 Mar;38(2):153-9
references.pmid: 19801178
references.citation: N Engl J Med. 2003 Sep 4;349(10):949-58
references.pmid: 12954743
references.citation: Ann Fam Med. 2007 Mar-Apr;5(2):146-50
references.pmid: 17389539
references.citation: J Gen Intern Med. 2009 Feb;24(2):226-32
references.pmid: 19089508
references.citation: CMAJ. 2009 Dec 8;181(12):891-6
references.pmid: 19969578
references.citation: Subst Abus. 2011 Oct;32(4):262-5
references.pmid: 22014257